.jpeg)
2026-04-30 04:02:14
This article comprehensively reviews the latest research progress of vibegron in 2026, covering its core efficacy verification in overactive bladder (OAB), long-term safety evaluation, and expanded application in male patients with concomitant benign prostatic hyperplasia, analyzing key clinical trial data and clinical value.
2026-04-20 04:21:47
Enfortumab vedotin (brand name Padcev) is the world's first Nectin-4-targeted antibody-drug conjugate (ADC) co-developed by Seagen and Astellas. It has been approved by the FDA, EMA, and other global regulatory agencies for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma.
2026-04-03 06:00:38
Rucaparib (brand name Rubraca) is a highly selective oral PARP inhibitor, granted full regular approval by the U.S. FDA on December 17, 2025, for the treatment of adult patients with deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). This approval is based on pivotal data from the phase III TRITON3 trial, marking the conversion from accelerated approval to full approval, and providing a new precision targeted therapy option for patients with advanced prostate cancer.
